According to the American Brain Tumor Association, Glioblastomas (also called GBM) are malignant Grade IV tumors, where a large portion of tumor cells reproduce and divide at any given time. The tumor is predominantly made up of abnormal astrocytic cells, which also contain a mixture of different cell types (including blood vessels) and areas of dead cells (necrosis). Glioblastomas are infiltrative and invade into nearby regions of the brain. They can also sometimes spread to the opposite side of the brain through connection fibers (corpus callosum).
The diagnosis of GBM mainly includes the use of neurological examinations, imaging tests, and excising a sample of tissue for testing, i.e, biopsy. The mainstay of treatment for GBM is surgery, followed by radiation and chemotherapy. The primary objective of surgery is to remove as much of the tumor as possible without injuring the surrounding normal brain tissue needed for normal neurological function (such as motor skills, the ability to speak and walk, etc.).
Get FREE sample copy at: https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market
The Recurrent Glioblastoma market report also covers emerging drugs, current treatment practices, Recurrent Glioblastoma market share of the individual therapies, current and forecasted Recurrent Glioblastoma Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Recurrent Glioblastoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Recurrent Glioblastoma Market Key Facts
-
The total incident population of Glioblastoma in the seven major markets was found to be 28,886 in 2017, which is expected to increase by 2030.
-
Most incident cases of Glioblastoma were recorded in the United States, i.e., 13,688 in 2017.
-
Among the European 5 countries, the United Kingdom had the highest incident population of GBM, followed by France and Italy. On the other hand, Spain had the lowest incident population of GBM.
-
According to a study conducted by Norden et al. titled “A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States”, despite the treatment options available to newly diagnosed patients, more than 50% of patients with GBM experience recurrence within 7 months of undergoing treatment.
Key Benefits of Recurrent Glioblastoma Market Report
-
Recurrent Glioblastoma market report provides an in-depth analysis of Recurrent Glioblastoma Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Recurrent Glioblastoma market report will help in developing business strategies by understanding the Recurrent Glioblastoma Market trends & developments, key players, and future market competition that will shape and drive the Recurrent Glioblastoma market in the upcoming years.
-
The Recurrent Glioblastoma market report covers Recurrent Glioblastoma current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Recurrent Glioblastoma market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Recurrent Glioblastoma market size is expected to increase during the forecast period owing to the rise in the number of incident cases in the 7MM.
The Recurrent Glioblastoma market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Recurrent Glioblastoma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Recurrent Glioblastoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Recurrent Glioblastoma Epidemiology
The Recurrent Glioblastoma epidemiology section covers insights about the historical and current Recurrent Glioblastoma patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Recurrent Glioblastoma Drugs Uptake and Key Market Players
The Recurrent Glioblastoma Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Recurrent Glioblastoma market or expected to get launched in the market during the study period. The analysis covers Recurrent Glioblastoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamic of the Recurrent GBM market is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise efficient treatment options. The Recurrent GBM pipeline is robust and possesses multiple potential drugs in late and mid-stage Developments. The launch of emerging therapies is expected during the forecast period.
Recurrent Glioblastoma Pipeline Therapies and Companies:
-
Immuncell-LC: Green Cross Cell Corporation
-
Marizomib: Celgene
-
Dianhydrogalactitol (VAL-083): DelMar Pharmaceuticals
-
Ofranergene obadenovec (VB-111): VBL Therapeutics
-
Depatuxizumab mafodotin (ABT-414): AbbVie
-
Trans Sodium Crocetinate: Diffusion Pharmaceuticals
-
Siroquine (JP001): Johnpro Biotech
-
Nivolumab: Bristol-Myers Squibb/Ono Pharmaceuticals
-
Ipilimumab: Bristol-Myers Squibb
-
Asunercept: Apogenix
-
Toca 511 and Toca FC: Tocagen
-
TTAC-0001: PharmAbcine
And many others
Table of Content
1. Key Insights
2. Executive Summary
3. Recurrent Glioblastoma Competitive Intelligence Analysis
4. Recurrent Glioblastoma Market Overview at a Glance
5. Recurrent Glioblastoma Disease Background and Overview
6. Recurrent Glioblastoma Patient Journey
7. Recurrent Glioblastoma Epidemiology and Patient Population
8. Recurrent Glioblastoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Recurrent Glioblastoma Unmet Needs
10. Key Endpoints of Recurrent Glioblastoma Treatment
11. Recurrent Glioblastoma Marketed Products
12. Recurrent Glioblastoma Emerging Therapies
13. Recurrent Glioblastoma Seven Major Market Analysis
14. Attribute Analysis
15. Recurrent Glioblastoma Market Outlook (7 major markets)
16. Recurrent Glioblastoma Access and Reimbursement Overview
17. KOL Views on the Recurrent Glioblastoma Market.
18. Recurrent Glioblastoma Market Drivers
19. Recurrent Glioblastoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/recurrent-glioblastoma-market
Latest Reports By DelveInsight
Recurrent Glioblastoma Pipeline Insights
Recurrent Glioblastoma Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Recurrent Glioblastoma market.
Healthcare Blogs –
Chronic Pain Associated with Painful Diabetic Neuropathy Market Analysis
As per DelveInsight’s, the Chronic Pain associated with the Painful Diabetic Neuropathy market is estimated to increase due to advancements in healthcare technology, high healthcare expenditure, and available reimbursement policies in developed countries. The key companies operating in the Chronic Pain associated with PDN market include Grünenthal, Daiichi Sankyo, Janssen Pharmaceutical, Pfizer, Eli Lilly, Shionogi, Fremslife, Helixmith, Aptinyx, Regenacy, Novaremed AG, Nevro., Erchonia Corporation, Regenesis Biomedical, Abbott, Zygood, and many others. For more details, visit: Chronic Pain Associated with Painful Diabetic Neuropathy Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/